Norelgestromin + ethinylestradiol

Generic Medicine Info
Thrombophlebitis, thromboembolic disorders, history of deep vein thromboembolic disorders, cerebrovascular or coronary artery disease, valvular heart disease with complications, severe hypertension, DM with vascular involvement, headaches with focal neurological symptoms, major surgery with prolonged immobilisation. Known or suspected carcinoma of the breast or history of breast cancer, carcinoma of the endometrium or other known or suspected estrogen-dependent neoplasia, undiagnosed abnormal genital bleeding, cholestatic jaundice of pregnancy or jaundice with prior hormonal contraceptive use. Acute or chronic hepatocellular disease with abnormal liver function, hepatic adenomas or carcinomas. Known or suspected pregnancy.
Special Precautions
Increased risk of CV side effects when used in women >35 yr and/or smokers. Women with other underlying risk factors for coronary artery disease such as hypertension, hypercholesterolaemia, morbid obesity and DM.
Adverse Reactions
Breast symptoms, headache, application site reaction, nausea, upper respiratory infection, menstrual cramps and abdominal pain. Changes in wt, cervical erosion and secretion. Diminution in lactation when given immediately postpartum, cholestatic jaundice , migraine, rash (allergic), mental depression, reduced tolerance to carbohydrates, vaginal candidiasis, changes in corneal curvature, intolerance to contact lenses.
Drug Interactions
Contraceptive efficacy may be reduced when used with barbiturates, griseofulvin, rifampicin, phenylbutazone, phenytoin, carbamazepine, felbamate, oxcarbazepine, topiramate and ampicillin. Efficacy may be affected when used with HIV protease inhibitors. May raise the serum levels of ciclosporin, prednisolone and theophylline. May increase clearance of temazepam, salicylic acid, morphine and clofibric acid.
Disclaimer: This information is independently developed by CIMS based on norelgestromin + ethinylestradiol from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 CIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in